Literature DB >> 10374878

Inhibition of constitutively activated Stat3 correlates with altered Bcl-2/Bax expression and induction of apoptosis in mycosis fungoides tumor cells.

M Nielsen1, C G Kaestel, K W Eriksen, A Woetmann, T Stokkedal, K Kaltoft, C Geisler, C Röpke, N Odum.   

Abstract

The Jak/Stat signaling pathway transmits signals from many cytokine and growth factor receptors to target genes in the nucleus. Constitutive activation of Stat3 has recently been observed in many tumor cells and dysregulation of the Stat signaling pathway has been proposed to be implicated in malignant transformation. In a previous study, we found constitutively tyrosine phosphorylated Stat3 in mycosis fungoides tumor cells. Here, we show that the Jak kinase inhibitor, Ag490, inhibits the constitutive binding of Stat3 to an oligonucleotide representing the Stat-binding sequence from the ICAM promotor. The decreased ability of Stat3 to bind DNA precedes dynamic alterations in the expression of anti-apoptotic Bcl-2 and pro-apoptotic Bax proteins (decreased Bcl-2 expression and increased Bax expression) and induction of apoptosis. Thus, our data suggest that the involvement of Stat3 in oncogenic transformation could be mediated through regulation of survival signals.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10374878     DOI: 10.1038/sj.leu.2401415

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  59 in total

1.  Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses.

Authors:  Ling-Yuan Kong; Adam S Wu; Tiffany Doucette; Jun Wei; Waldemar Priebe; Gregory N Fuller; Wei Qiao; Raymond Sawaya; Ganesh Rao; Amy B Heimberger
Journal:  Clin Cancer Res       Date:  2010-10-04       Impact factor: 12.531

2.  v-Src generates a p53-independent apoptotic signal.

Authors:  B L Webb; E Jimenez; G S Martin
Journal:  Mol Cell Biol       Date:  2000-12       Impact factor: 4.272

3.  Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins.

Authors:  Anders Woetmann; Paola Lovato; Karsten W Eriksen; Thorbjørn Krejsgaard; Tord Labuda; Qian Zhang; Anne-Merethe Mathiesen; Carsten Geisler; Arne Svejgaard; Mariusz A Wasik; Niels Ødum
Journal:  Blood       Date:  2006-12-19       Impact factor: 22.113

4.  Exploring the IL-21-STAT3 axis as therapeutic target for Sézary syndrome.

Authors:  Leslie van der Fits; Jacoba J Out-Luiting; Cornelis P Tensen; Willem H Zoutman; Maarten H Vermeer
Journal:  J Invest Dermatol       Date:  2014-04-22       Impact factor: 8.551

5.  Anticancer efficacy of a difluorodiarylidenyl piperidone (HO-3867) in human ovarian cancer cells and tumor xenografts.

Authors:  Karuppaiyah Selvendiran; Liyue Tong; Anna Bratasz; M Lakshmi Kuppusamy; Shabnam Ahmed; Yazhini Ravi; Nancy J Trigg; Brian K Rivera; Tamás Kálai; Kálmán Hideg; Periannan Kuppusamy
Journal:  Mol Cancer Ther       Date:  2010-05-04       Impact factor: 6.261

Review 6.  Cytokine-induced tumor suppressors: a GRIM story.

Authors:  Dhan V Kalvakolanu; Shreeram C Nallar; Sudhakar Kalakonda
Journal:  Cytokine       Date:  2010-04-10       Impact factor: 3.861

7.  Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth.

Authors:  Paul L Leong; Genevieve A Andrews; Daniel E Johnson; Kevin F Dyer; Sichuan Xi; Jeffrey C Mai; Paul D Robbins; Seshu Gadiparthi; Nancy A Burke; Simon F Watkins; Jennifer Rubin Grandis
Journal:  Proc Natl Acad Sci U S A       Date:  2003-03-14       Impact factor: 11.205

8.  Analysis of STAT4 expression in cutaneous T-cell lymphoma (CTCL) patients and patient-derived cell lines.

Authors:  Ivan V Litvinov; Brendan Cordeiro; Simon Fredholm; Niels Ødum; Hanieh Zargham; Yuanshen Huang; Youwen Zhou; Kevin Pehr; Thomas S Kupper; Anders Woetmann; Denis Sasseville
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

9.  Deregulation in STAT signaling is important for cutaneous T-cell lymphoma (CTCL) pathogenesis and cancer progression.

Authors:  Elena Netchiporouk; Ivan V Litvinov; Linda Moreau; Martin Gilbert; Denis Sasseville; Madeleine Duvic
Journal:  Cell Cycle       Date:  2014       Impact factor: 4.534

10.  Ectopic expression of B-lymphoid kinase in cutaneous T-cell lymphoma.

Authors:  Thorbjørn Krejsgaard; Claudia S Vetter-Kauczok; Anders Woetmann; Hermann Kneitz; Karsten W Eriksen; Paola Lovato; Qian Zhang; Mariusz A Wasik; Carsten Geisler; Elisabeth Ralfkiaer; Juergen C Becker; Niels Ødum
Journal:  Blood       Date:  2009-04-07       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.